{
  "url": "https://finance.yahoo.com/news/south-harz-potash-insiders-placed-002510663.html?_guc_consent_skip=1756083275",
  "authorsByline": "Simply Wall St",
  "articleId": "e18c73dd50b64dcfb10eabe40680f089",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/3eb1acfa01a97be66f224c62f2ff60fd",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-25T00:25:10+00:00",
  "addDate": "2025-08-25T00:55:40.483382+00:00",
  "refreshDate": "2025-08-25T00:55:40.483385+00:00",
  "score": 1.0,
  "title": "South Harz Potash Insiders Placed Bullish Bets Worth AU$817.3k",
  "description": "Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...",
  "content": "Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of South Harz Potash Limited (ASX:SHP), it sends a favourable message to the company's shareholders.\n\nAlthough we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.\n\nAI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.\n\nThe Last 12 Months Of Insider Transactions At South Harz Potash\n\nThe Executive Chairman Leonard Jubber made the biggest insider purchase in the last 12 months. That single transaction was for AU$194k worth of shares at a price of AU$0.15 each. That means that even when the share price was higher than AU$0.035 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.\n\nWhile South Harz Potash insiders bought shares during the last year, they didn't sell. Their average price was about AU$0.11. This is nice to see since it implies that insiders might see value around current prices. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!\n\nCheck out our latest analysis for South Harz Potash\n\nThere are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.\n\nOver the last quarter, South Harz Potash insiders have spent a meaningful amount on shares. Overall, three insiders shelled out AU$107k for shares in the company -- and none sold. This is a positive in our book as it implies some confidence.\n\nMany investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own AU$534k worth of South Harz Potash stock, about 2.8% of the company. We prefer to see high levels of insider ownership.",
  "medium": "Article",
  "links": [
    "https://au.finance.yahoo.com/quote/SHP.AX",
    "https://simplywall.st/discover/investing-ideas/16951/undervalued-small-caps-with-insider-buying?blueprint=4013719&utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo",
    "https://simplywall.st/company/id/492B3C7A-828E-4D0E-BEDD-F0C5453896B2?blueprint=4013719&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
    "https://simplywall.st/company/id/492B3C7A-828E-4D0E-BEDD-F0C5453896B2/ownership?blueprint=4013719&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
    "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4013719&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "South Harz Potash Insiders",
      "weight": 0.15915792
    },
    {
      "name": "South Harz Potash insiders",
      "weight": 0.15915792
    },
    {
      "name": "Insider Transactions",
      "weight": 0.14264922
    },
    {
      "name": "insider transactions",
      "weight": 0.14264922
    },
    {
      "name": "insiders",
      "weight": 0.13576056
    },
    {
      "name": "insider ownership",
      "weight": 0.13440165
    },
    {
      "name": "several insiders",
      "weight": 0.13096663
    },
    {
      "name": "South Harz Potash",
      "weight": 0.12594385
    },
    {
      "name": "South Harz Potash stock",
      "weight": 0.12484416
    },
    {
      "name": "South Harz Potash Limited",
      "weight": 0.12040288
    }
  ],
  "topics": [],
  "categories": [],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.994140625
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.9892578125
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.9853515625
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.7744140625
    },
    {
      "name": "/Finance/Investing/Other",
      "score": 0.3779296875
    }
  ],
  "sentiment": {
    "positive": 0.17739412,
    "negative": 0.22439094,
    "neutral": 0.5982149
  },
  "summary": "South Harz Potash Limited (ASX:SHP) has made significant purchases worth AU$817.3k in the last year, with the Executive Chairman making the largest in the year at AU$194k worth of shares at a price of AU$0.15 each. This indicates that several insiders are actively investing in the company. While these purchases may cause regret, it is more likely they are bullish about the company's future. Over the last quarter, three insiders purchased AU$107k for shares, which indicates some confidence in insider activity. The chart below shows insider transactions over the past year.",
  "shortSummary": "South Harz Potash's insider purchases indicate confidence in the company's long-term prospects, with significant investments in both companies and stock markets.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "8c9fa41ec0584368be2f0337254b5f60",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4013719&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
      "text": "Results\n27\nArtificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research. AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription. It powers telemedicine, monitors chronic conditions in real-time, and speeds up drug discovery by analyzing vast datasets for insights into complex diseases. Despite challenges like data privacy, bias, and integration costs, AI\u2019s ability to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery and outcomes.\n27 companies\nRakovina Therapeutics\nMarket Cap: US$10.8m\nA biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.\nRKVT.F\nUS$0.37\n7D\n-9.8%\n1Y\nn/a\nCosmo Pharmaceuticals\nMarket Cap: US$924.5m\nFocuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.\nCMOP.F\nUS$75.00\n7D\n0%\n1Y\nn/a\nGubra\nMarket Cap: US$5.8b\nA biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.\nGUBR.F\nUS$60.15\n7D\n0%\n1Y\nn/a\nEvaxion\nMarket Cap: US$20.5m\nA clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.\nEVAX\nUS$3.25\n7D\n12.8%\n1Y\n-79.3%\nImmunoPrecise Antibodies\nMarket Cap: US$147.7m\nOperates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.\nIPA\nUS$3.20\n7D\n60.0%\n1Y\n295.1%\nEvolent Health\nMarket Cap: US$1.1b\nThrough its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States.\nEVH\nUS$9.60\n7D\n3.2%\n1Y\n-70.9%\nGeneDx Holdings\nMarket Cap: US$3.7b\nA genomics company, provides genetic testing services.\nWGS\nUS$128.67\n7D\n1.8%\n1Y\n259.8%\nWELL Health Technologies\nMarket Cap: US$1.2b\nOperates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.\nWHTC.F\nUS$3.56\n7D\n3.1%\n1Y\n1.1%\nSpectral AI\nMarket Cap: US$55.9m\nAn artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States.\nMDAI\nUS$2.09\n7D\n-0.9%\n1Y\n40.3%\nRevenio Group Oyj\nMarket Cap: US$657.1m\nProvides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.\nREVX.F\nUS$31.47\n7D\n0%\n1Y\nn/a\nRadNet\nMarket Cap: US$5.4b\nProvides outpatient diagnostic imaging services in the United States and internationally.\nRDNT\nUS$70.10\n7D\n3.9%\n1Y\n7.8%\nCareCloud\nMarket Cap: US$119.8m\nA healthcare information technology (IT) company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States.\nCCLD\nUS$2.83\n7D\n8.8%\n1Y\n-2.1%\nSimulations Plus\nMarket Cap: US$293.3m\nDevelops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.\nSLP\nUS$14.57\n7D\n2.3%\n1Y\n-60.4%\nGuardant Health\nMarket Cap: US$7.7b\nA precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.\nGH\nUS$61.40\n7D\n4.3%\n1Y\n111.6%\nNano-X Imaging\nMarket Cap: US$259.6m\nDevelops a commercial-grade tomographic imaging device with a digital X-ray source.\nNNOX\nUS$4.06\n7D\n-8.1%\n1Y\n-42.3%\nPerimeter Medical Imaging AI\nMarket Cap: US$26.2m\nA medical technology company, provides advanced imaging solutions to address unmet medical needs.\nPYNK.F\nUS$0.17\n7D\n-1.4%\n1Y\n-39.1%\nCeriBell\nMarket Cap: US$442.2m\nOperates as a medical technology company focuses on transforming the diagnosis and management of patients with serious neurological conditions in the United States.\nCBLL\nUS$12.06\n7D\n-2.0%\n1Y\nn/a\nHeartSciences\nMarket Cap: US$13.6m\nA medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.\nHSCS\nUS$3.65\n7D\n8.0%\n1Y\n-1.9%\nOmniAb\nMarket Cap: US$227.0m\nA biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.\nOABI\nUS$1.85\n7D\n-8.0%\n1Y\n-56.8%\nXtalPi Holdings\nMarket Cap: US$40.9b\nAn investment holding company, engages in the provision of robotics and drug discovery solutions in Mainland China, the United States, and internationally.\nQNTP.F\nUS$1.20\n7D\n14.3%\n1Y\nn/a\nNeuroOne Medical Technologies\nMarket Cap: US$39.2m\nA medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States.\nNMTC\nUS$0.78\n7D\n-4.3%\n1Y\n0.1%\nBioXcel Therapeutics\nMarket Cap: US$72.5m\nTogether with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.\nBTAI\nUS$4.98\n7D\n-9.1%\n1Y\n-54.2%\nLantheus Holdings\nMarket Cap: US$4.0b\nDevelops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.\nLNTH\nUS$58.21\n7D\n7.4%\n1Y\n-45.7%\nAbsci\nMarket Cap: US$483.3m\nOperates as a data-first generative artificial intelligence (AI) drug creation company in the United States.\nABSI\nUS$2.63\n7D\n-10.2%\n1Y\n-41.4%\nHealwell AI\nMarket Cap: US$383.8m\nA healthcare artificial intelligence company, develops and commercializes clinical decision support systems in Canada, New Zealand, Australia, and the United Kingdom.\nHWAI.F\nUS$0.99\n7D\n4.2%\n1Y\n-34.9%\nPersonalis\nMarket Cap: US$428.3m\nDevelops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.\nPSNL\nUS$4.83\n7D\n5.0%\n1Y\n-19.1%\nVeradigm\nMarket Cap: US$823.7m\nA healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally.\nMDRX\nUS$4.85\n7D\n5.4%\n1Y\n-50.0%"
    },
    {
      "url": "https://simplywall.st/company/id/492B3C7A-828E-4D0E-BEDD-F0C5453896B2/ownership?blueprint=4013719&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "South Harz Potash Ownership\nWho are the major shareholders and have insiders been buying or selling?\nRecent Insider Transactions\n| Date | Value | Name | Entity | Role | Shares | Max Price |\n|---|---|---|---|---|---|---|\n| 31 Jul 25 | BuyAU$31,504 | Leonard Jubber | Individual | 700,158.93 | AU$0.045 | |\n| 31 Jul 25 | BuyAU$7,999 | Reinout Koopmans | Individual | 177,778 | AU$0.045 | |\n| 31 Jul 25 | BuyAU$67,849 | Rory Luff | Individual | 1,507,915.2 | AU$0.045 | |\n| 12 May 25 | BuyAU$66,002 | Leonard Jubber | Individual | 440,000 | AU$0.15 | |\n| 12 May 25 | BuyAU$10,000 | Reinout Koopmans | Individual | 66,666.67 | AU$0.15 | |\n| 12 May 25 | BuyAU$75,503 | Rory Luff | Individual | 503,333.33 | AU$0.15 | |\n| 16 Dec 24 | BuyAU$193,688 | Leonard Jubber | Individual | 1,291,181.2 | AU$0.15 | |\n| 16 Dec 24 | BuyAU$80,826 | Reinout Koopmans | Individual | 538,813.93 | AU$0.15 | |\n| 16 Dec 24 | BuyAU$176,677 | Rory Luff | Individual | 1,177,784.2 | AU$0.15 | |\n| 23 Sep 24 | BuyAU$13,242 | Leonard Jubber | Individual | 88,279.6 | AU$0.15 | |\n| 23 Sep 24 | BuyAU$94,018 | Rory Luff | Individual | 626,806.33 | AU$0.15 |\nInsider Trading Volume\nInsider Buying: SHP insiders have bought more shares than they have sold in the past 3 months.\nOwnership Breakdown\n| Owner Type | Number of Shares | Ownership Percentage |\n|---|---|---|\n| Institutions | 3,026,667 | 3.08% |\n| Private Companies | 3,923,668 | 4% |\n| Individual Insiders | 15,269,440 | 15.6% |\n| General Public | 75,895,118 | 77.4% |\nDilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 817.8%.\nTop Shareholders\n| Ownership | Name | Shares | Current Value | Change % | Portfolio % | |\n|---|---|---|---|---|---|---|\n| 6,041,327 | AU$1.2m | 33.3% | no data | |||\n| 2,800,636 | AU$544.1k | 33.3% | no data | |||\n| 2,000,000 | AU$388.6k | 0% | no data | |||\n| 1,713,886 | AU$333.0k | 0% | no data | |||\n| 1,248,521 | AU$242.6k | 16.6% | no data | |||\n| 1,137,417 | AU$221.0k | 0% | no data | |||\n| 900,000 | AU$174.9k | 0% | 0.8% | |||\n| 877,037 | AU$170.4k | 0% | no data | |||\n| 826,667 | AU$160.6k | 0% | 0.01% | |||\n| 738,893 | AU$143.6k | 0% | no data | |||\n| 733,333 | AU$142.5k | 0% | no data | |||\n| 700,000 | AU$136.0k | 0% | 0.37% | |||\n| 600,000 | AU$116.6k | 0% | 0.12% | |||\n| 599,412 | AU$116.5k | 0% | no data | |||\n| 506,667 | AU$98.4k | 0% | no data | |||\n| 295,556 | AU$57.4k | 0% | no data | |||\n| 295,556 | AU$57.4k | 0% | no data | |||\n| 150,768 | AU$29.3k | 0% | no data | |||\n| 54,099 | AU$10.5k | 0% | no data |\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/24 19:26 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2024/12/31 |\n| Annual Earnings | 2024/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nSouth Harz Potash Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Roger Bell | Hannam & Partners (Advisory) LLP |"
    },
    {
      "url": "https://simplywall.st/company/id/492B3C7A-828E-4D0E-BEDD-F0C5453896B2?blueprint=4013719&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
      "text": "South Harz Potash (SHP) Stock Overview\nExplores for and develops mineral properties in Germany. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 0/6 |\n| Future Growth | 0/6 |\n| Past Performance | 0/6 |\n| Financial Health | 5/6 |\n| Dividends | 0/6 |\nSHP Community Fair Values\nSee what others think this stock is worth. Follow their fair value or set your own to get alerts.\nSouth Harz Potash Limited Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | AU$0.035 |\n| 52 Week High | AU$0.21 |\n| 52 Week Low | AU$0.03 |\n| Beta | 0.57 |\n| 1 Month Change | -41.67% |\n| 3 Month Change | -48.15% |\n| 1 Year Change | -76.67% |\n| 3 Year Change | -96.57% |\n| 5 Year Change | -94.02% |\n| Change since IPO | -98.80% |\nRecent News & Updates\nRecent updates\nWe're Hopeful That South Harz Potash (ASX:SHP) Will Use Its Cash Wisely\nJul 14Companies Like South Harz Potash (ASX:SHP) Are In A Position To Invest In Growth\nOct 04Will South Harz Potash (ASX:SHP) Spend Its Cash Wisely?\nJun 21Did Davenport Resources Limited (ASX:DAV) Insiders Buy Up More Shares?\nFeb 27Shareholder Returns\n| SHP | AU Metals and Mining | AU Market | |\n|---|---|---|---|\n| 7D | -6.7% | -0.8% | 0.2% |\n| 1Y | -76.7% | 12.2% | 11.4% |\nReturn vs Industry: SHP underperformed the Australian Metals and Mining industry which returned 12.2% over the past year.\nReturn vs Market: SHP underperformed the Australian Market which returned 11.4% over the past year.\nPrice Volatility\n| SHP volatility | |\n|---|---|\n| SHP Average Weekly Movement | 43.9% |\n| Metals and Mining Industry Average Movement | 11.2% |\n| Market Average Movement | 8.8% |\n| 10% most volatile stocks in AU Market | 18.9% |\n| 10% least volatile stocks in AU Market | 3.2% |\nStable Share Price: SHP's share price has been volatile over the past 3 months compared to the Australian market.\nVolatility Over Time: SHP's weekly volatility has increased from 30% to 44% over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 2011 | n/a | n/a | southharzpotash.com |\nSouth Harz Potash Limited explores for and develops mineral properties in Germany. It primarily explores for potash deposits. The company's flagship project Ohmgebirge which is located in the Thuringia, Germany.\nSouth Harz Potash Limited Fundamentals Summary\n| SHP fundamental statistics | |\n|---|---|\n| Market cap | AU$19.06m |\n| Earnings (TTM) | -AU$5.03m |\n| Revenue (TTM) | n/a |\nIs SHP overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| SHP income statement (TTM) | |\n|---|---|\n| Revenue | AU$0 |\n| Cost of Revenue | AU$0 |\n| Gross Profit | AU$0 |\n| Other Expenses | AU$5.03m |\n| Earnings | -AU$5.03m |\nLast Reported Earnings\nDec 31, 2024\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | -0.0092 |\n| Gross Margin | 0.00% |\n| Net Profit Margin | 0.00% |\n| Debt/Equity Ratio | 0% |\nHow did SHP perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/24 19:26 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2024/12/31 |\n| Annual Earnings | 2024/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nSouth Harz Potash Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Roger Bell | Hannam & Partners (Advisory) LLP |"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/16951/undervalued-small-caps-with-insider-buying?blueprint=4013719&utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo",
      "text": "Results\n14\nSmaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.\n14 companies\nHoist Finance\nMarket Cap: SEK 9.0b\nA credit market company, engages in the loan acquisition and management operations in Europe.\nHOFI\nSEK 103.50\n7D\n2.5%\n1Y\n31.5%\nNyab\nMarket Cap: SEK 5.0b\nProvides engineering, construction, and maintenance services to energy, infrastructure, and industrial construction projects for public and private sectors in Finland and Sweden.\nNYAB\nSEK 7.01\n7D\n-3.0%\n1Y\n2.5%\nDi\u00f6s Fastigheter\nMarket Cap: SEK 9.4b\nDevelops, owns, and rents commercial and residential properties in Sweden.\nDIOS\nSEK 66.10\n7D\n2.6%\n1Y\n-26.8%\nMilDef Group\nMarket Cap: SEK 7.1b\nDevelops, manufactures, and sells rugged IT solutions in Sweden, Norway, Finland, Denmark, the United Kingdom, Germany, Switzerland, the United States, Australia, and internationally.\nMILDEF\nSEK 150.80\n7D\n-1.6%\n1Y\n92.1%\nClavister Holding AB (publ.)\nMarket Cap: SEK 1.3b\nDevelops, produces, and sells cybersecurity solutions in Sweden, rest of Europe, Asia, and internationally.\nCLAV\nSEK 4.34\n7D\n-1.4%\n1Y\n182.7%\nLogistea\nMarket Cap: SEK 8.4b\nEngages in the real estate business in Sweden, Norway, Denmark, the Netherlands, Germany, Finland, Belgium, and Poland.\nLOGI A\nSEK 16.20\n7D\n0%\n1Y\n-3.0%\nNew Wave Group\nMarket Cap: SEK 14.4b\nDesigns, acquires, and develops brands and products in the corporate, sports, gifts, and home furnishings sectors in Sweden, the United States, Central Europe, rest of Nordiac countries, Southern Europe, and internationally.\nNEWA B\nSEK 108.50\n7D\n3.2%\n1Y\n-2.7%\nNolato\nMarket Cap: SEK 15.8b\nDevelops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally.\nNOLA B\nSEK 58.50\n7D\n2.6%\n1Y\n7.8%\nEgetis Therapeutics\nMarket Cap: SEK 1.9b\nA pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment.\nEGTX\nSEK 5.20\n7D\n-4.8%\n1Y\n-10.3%\nInwido\nMarket Cap: SEK 11.0b\nThrough its subsidiaries, engages in development, manufacture, and sale of windows and doors in Sweden.\nINWI\nSEK 190.00\n7D\n3.3%\n1Y\n6.9%\nPlatzer Fastigheter Holding\nMarket Cap: SEK 8.6b\nOperates as a commercial real estate company in Sweden.\nPLAZ B\nSEK 71.40\n7D\n1.7%\n1Y\n-30.4%\nArbona\nMarket Cap: SEK 1.8b\nInvests in small and medium sized listed and unlisted companies in Sweden.\nARBO A\nSEK 3.41\n7D\n-0.6%\n1Y\n0.9%\nVimian Group\nMarket Cap: SEK 16.9b\nEngages in the animal health business worldwide.\nVIMIAN\nSEK 32.32\n7D\n4.0%\n1Y\n-20.8%\nNet Insight\nMarket Cap: SEK 1.5b\nProvides media network solutions worldwide.\nNETI B\nSEK 4.52\n7D\n8.1%\n1Y\n-32.6%"
    }
  ],
  "argos_summary": "South Harz Potash Limited (ASX:SHP) has seen significant insider buying, with key executives Leonard Jubber, Reinout Koopmans and Rory Luff purchasing shares at prices above current levels, indicating bullish sentiment. Despite this, the company remains heavily diluted, with shares outstanding up 817.8% in the past year, and its stock has underperformed the Australian metals and mining sector, dropping 76.7% over the last year. Financially, SHP reports a negative earnings of AU$5.03m and zero revenue, with a market cap of AU$19.06m and a current share price of AU$0.035. The stock exhibits high volatility, with weekly swings approaching 44%, and has no dividends. The article also lists a broad set of AI\u2011driven healthcare and other small\u2011cap companies, but the primary focus is on SHP's insider activity and market performance.",
  "argos_id": "XZE0194FG"
}